膜杰作
Star Staining
分子别名（Synonym）
phosphodiesterase 4A,cAMP-specific 3',5'-cyclic phosphodiesterase 4A,
表达区间及表达系统（Source）
Human PDE4A Protein, His Tag (PDA-H55H3) is expressed from Baculovirus-Insect cells. It contains AA Pro 331 - Met 723 (Accession # P27815-1).
Predicted N-terminus: Met
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 47.1 kDa. The protein migrates as 45-52 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, 1 mM DTT, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
电泳（SDS-PAGE）
Human PDE4A Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human PDE4A Protein, His Tag (Cat. No. PDA-H55H3) is more than 90% and the molecular weight of this protein is around 48-68 kDa verified by SEC-MALS.
Report
活性（Bioactivity）
Measured by its ability to convert cAMP to 5'AMP. The specific activity is >140,000 pmol/min/μg (QC tested).
Protocol
背景（Background）
cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A) is an enzyme that in humans is encoded by the PDE4A gene. It belongs to the PDE family who hydrolyze 3′-5′-cyclic adenosine monophosphate (cyclic AMP) to 5′-adenosine monophosphate (AMP). PDE enzyme family plays a pivotal role in regulating levels of the second messenger cAMP. Consequently, PDE4 inhibitors have been investigated as a therapeutic strategy to enhance cAMP signaling in a broad range of diseases, including several types of cancers, as well as in various neurologic, dermatological, and inflammatory diseases.
